Загрузка...
Are We Sure that Adjuvant Chemotherapy is the Best Approach for Resectable Pancreatic Cancer? Are We in the Era of Neoadjuvant Treatment? A Review of Current Literature
The outcome of pancreatic cancer is poor, with a 9% 5-year survival rate. Current treatment recommendations in the 10%−20% of patients who present with resectable disease support upfront resection followed by adjuvant therapy. Until now, only early complete surgical (R0) resection and adju...
Сохранить в:
| Главные авторы: | , |
|---|---|
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
MDPI AG
2019-11-01
|
| Серии: | Journal of Clinical Medicine |
| Предметы: | |
| Online-ссылка: | https://www.mdpi.com/2077-0383/8/11/1922 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|